Steven Cohen Point72 Asset Management
Steven Cohen is the founder of Point72 Asset Management and previously built SAC Capital into one of the industry’s most profitable trading firms. Point72 operates a multi-manager platform combining fundamental long/short equity with systematic and other strategies. Cohen is also a major figure in sports ownership and philanthropy, while remaining one of the most closely followed names in hedge fund trading culture.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Palantir
PLTR
|
+$284M |
| 2 |
Alphabet (Google) Class A
GOOGL
|
+$243M |
| 3 |
Eli Lilly
LLY
|
+$204M |
| 4 |
Meta Platforms (Facebook)
META
|
+$191M |
| 5 |
Microsoft
MSFT
|
+$134M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IMMU
Immunomedics Inc
IMMU
|
+$205M |
| 2 |
Merck
MRK
|
+$169M |
| 3 |
Canadian National Railway
CNI
|
+$131M |
| 4 |
NXP Semiconductors
NXPI
|
+$119M |
| 5 |
Fidelity National Information Services
FIS
|
+$119M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 22.77% |
| 2 | Technology | 20.47% |
| 3 | Consumer Discretionary | 13.53% |
| 4 | Financials | 8.97% |
| 5 | Communication Services | 7.71% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
WWE
351
DELISTED
World Wrestling Entertainment
WWE
| $13.1M | 0.07% |
+324,144
| New | +$14.2M |
|
|
352
Fidelity National Information Services
FIS
$21.4B
| $13.1M | 0.07% |
88,860
-826,290
| -90% | -$119M |
|
353
Intellia Therapeutics
NTLA
$1.76B
| $13M | 0.07% |
653,119
-217,788
| -25% | -$4.54M |
|
354
CALL
Royal Caribbean
RCL
$78.4B
| $12.9M | 0.07% |
+200,000
| New | +$11.8M |
|
|
STMP
355
DELISTED
Stamps.com, Inc.
STMP
| $12.9M | 0.07% |
53,665
-9,588
| -15% | -$2.29M |
|
356
Cogent Communications
CCOI
$486M
| $12.9M | 0.07% |
215,065
+124,142
| +137% | +$9.06M |
|
|
OTIC
357
DELISTED
Otonomy, Inc.
OTIC
| $12.9M | 0.07% |
3,184,497
+2,210,238
| +227% | +$8.33M |
|
|
CALA
358
DELISTED
Calithera Biosciences, Inc
CALA
| $12.9M | 0.07% |
186,375
-18,697
| -9% | -$1.63M |
|
359
Assurant
AIZ
$14.2B
| $12.8M | 0.07% |
105,894
+34,160
| +48% | +$3.92M |
|
360
McCormick & Company Non-Voting
MKC
$15.1B
| $12.8M | 0.07% |
131,602
+90,802
| +223% | +$8.89M |
|
361
Stanley Black & Decker
SWK
$14.9B
| $12.8M | 0.07% |
+78,743
| New | +$12.3M |
|
|
ZGNX
362
DELISTED
Zogenix, Inc.
ZGNX
| $12.7M | 0.07% |
708,462
+542,954
| +328% | +$13.3M |
|
363
Universal Health Services
UHS
$10.4B
| $12.7M | 0.06% |
+118,232
| New | +$12.6M |
|
364
CALL
Pinterest
PINS
$13.3B
| $12.5M | 0.06% |
+300,000
| New | +$9.78M |
|
|
SURF
365
DELISTED
Surface Oncology, Inc. Common Stock
SURF
| $12.4M | 0.06% |
+1,804,020
| New | +$10.9M |
|
366
Expedia Group
EXPE
$40.7B
| $12.4M | 0.06% |
135,522
-549,495
| -80% | -$49.4M |
|
|
APTO
367
DELISTED
Aptose Biosciences, Inc.
APTO
| $12.4M | 0.06% |
+4,593
| New | +$11.5M |
|
368
AES
AES
$10.5B
| $12.3M | 0.06% |
680,946
+478,636
| +237% | +$8M |
|
369
DaVita
DVA
$11.3B
| $12.3M | 0.06% |
+143,690
| New | +$12.3M |
|
370
Charles River Laboratories
CRL
$14.3B
| $12.1M | 0.06% |
+53,472
| New | +$11.1M |
|
371
10x Genomics
TXG
$8.31B
| $12.1M | 0.06% |
97,077
+55,992
| +136% | +$5.88M |
|
372
Brinker International
EAT
$10.9B
| $12.1M | 0.06% |
283,223
+54,189
| +24% | +$1.89M |
|
|
X
373
DELISTED
US Steel
X
| $12M | 0.06% |
+1,634,933
| New | +$12.4M |
|
374
Neurogene
NGNE
$793M
| $12M | 0.06% |
49,985
+25,435
| +104% | +$6.16M |
|
375
Fulcrum Therapeutics
FULC
$293M
| $12M | 0.06% |
1,510,000
+1,249,303
| +479% | +$15M |
|
Similar funds
Steven Cohen's Q3 2020 Portfolio in Review
As of Q3 2020, Steven Cohen held 1,184 positions worth $19.5B, up 27% from $15.3B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
Steven Cohen deployed $3.06B of net new capital in Q3 2020, opening 406 new positions and adding to 253 existing holdings. Its largest new stake was Palantir: 29,904,230 shares worth $284M.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 23% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Immunomedics Inc, an estimated $205M trimmed.
- Steven Cohen's largest Q3 2020 buy was Palantir: 29,904,230 shares worth $284M.
- Steven Cohen added most to Alphabet (Google) Class A in Q3 2020, an estimated $243M increase.
- Steven Cohen's biggest Q3 2020 reduction was Immunomedics Inc, cutting an estimated $205M.
- Steven Cohen fully exited Salesforce in Q3 2020, selling an estimated $105M.
- Steven Cohen's ten largest holdings make up 16% of its $19.5B portfolio in Q3 2020.
- Steven Cohen opened 406 new positions and closed 288 in Q3 2020.
- Steven Cohen's portfolio value rose 27% quarter-over-quarter to $19.5B.
Based on Point72 Asset Management's 13F filing for Q3 2020, filed 16 Nov 2020.